CD274 and neoplasm: Cemiplimab, a human PD-1 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, has been approved as monotherapy for advanced NSCLC with PD-L1 expression in more than 50% tumor cells (64, 65).